As the list of diseases treated with auto-ASCT grows, it is inevitable that patients with a solid organ transplant will undergo auto-SCT. In immunoglobulin light chain (AL) amyloidosis, auto-SCT is performed in combination with kidney transplantation in those who developed end-stage kidney disease. 1 The management of immunosuppression immediately after auto-SCT can be difficult as overimmunosuppression raises the risk of infection, whereas underimmunosuppression may result in acute rejection. We present a case to illustrate the complexity of this management.
A previously healthy 58-year-old man presented with fatigue, anemia and a serum creatinine (Scr) level of 4.5 mg/ 100 ml. A monoclonal lambda light chain was identified in the blood and urine, and the bone marrow showed 11% lambda-restricted plasma cells. Renal biopsy confirmed the diagnosis of AL amyloidosis. After 4 months, he was started on hemodialysis. With no evidence of cardiac or hepatic involvement, a living unrelated donor kidney transplantation (Ktx) followed by auto-SCT was planned. His wife (0 of 6 antigen match) was selected as the donor.
At 8 months after his diagnosis, stem cells were collected prior to the Ktx. Pre-kidney transplant screening using flow cytometry of purified HLA antigens bound to synthetic microspheres (Luminex) showed donor-specific anti-HLA class I and II antibodies (A29 and DR4). However, T-and B-cell flow cytometric cross-matches were negative. Induction immunosuppression was achieved with standard antilymphocyte antibody (Thymoglobulin), tacrolimus, mycophenolate mofetil (MMF) and corticosteroids. The kidney transplant was performed without complications and Scr was stable at 1.7 mg/100 ml at 1 month posttransplant. The patient was scheduled to return in 3 months for auto-SCT.
At 6 weeks after Ktx, the patient returned with an Scr of 2.8 mg/100 ml. A renal allograft biopsy revealed no evidence of rejection. Tacrolimus level (measured by HPLC tandem mass spectrometry) was 11.9 ng/ml, which was felt to be the cause of the allograft dysfunction. Tacrolimus dose was reduced to 0.5 mg in the morning and 0.25 mg in the evening, and Scr stabilized at 1.9-2.1 mg/100 ml. Auto-SCT was performed 4 months after Ktx. Conditioning was performed with melphalan (200 mg/m 2 ). MMF was discontinued on the first day of conditioning, whereas tacrolimus was maintained at a level between 4 and 6 ng/ml. The patient developed the usual pancytopenia and neutrophils recovered on day þ 13. On day þ 15 (Figure 1 ), his Scr increased from 2.9 to 4.0 mg/100 ml. Tacrolimus level was 3.9 ng/ml. A renal allograft biopsy revealed mild to moderate interstitial inflammation along with tubulitis consistent with Banff 1A cellular rejection. 2 The single antigen bead assay that was negative 2 weeks earlier became positive on day þ 17 to several class II antigens including donor's DR4. B-cell flow cytometric cross-match became positive for the first time.
Methylprednisolone 500 mg/day was initiated. Tacrolimus target was increased to 7-10 ng/ml and MMF was restarted. Dialysis was initiated on day þ 18. A repeat biopsy on day þ 27 of auto-SCT showed ongoing diffuse tubulointerstitial infiltrates and tubulitis consistent with persistent acute cellular rejection (Banff IA). Immunohistochemistry stain showed that the mononuclear infiltrate consisted almost entirely of CD3 þ cells. C4d assay was negative. Antithymocyte globulin (Thymoglobulin) 100 mg/ day was started on day þ 28 for 7 days. Renal function improved rapidly and dialysis was discontinued after day þ 31. By day þ 38, Scr had decreased to 2.6 mg/100 ml. Another renal biopsy performed on day þ 43 showed complete resolution of the acute rejection with only residue acute tubular necrosis.
As this case illustrates, rejection can occur rapidly after leukocyte engraftment and can be severe (steroid resistant). Underimmunosuppression was probably responsible for the rejection episode. However, two other mechanisms may also have contributed. Calcineurin inhibitors have been used to induce autologous GVHD in an effort to elicit a graft versus tumor effect immediately after syngeneic or autologous hematopoietic SCT. 3 This autoaggression phenomenon is thought to be mediated by the inhibition of suppressor T cells and could have contributed to graft rejection. 4 It can be noted that our patient did not develop a skin rash, which is a common feature of autologous GVHD. Another factor may be the timing of the stem cell collection. The stem cells were collected prior to Ktx conditioning. Pre-sensitized lymphocytes could have been collected and reinfused during auto-SCT resulting in the rejection. Finally, a combination of the three mechanisms may have contributed.
To the best of our knowledge, acute cellular rejection of a kidney allograft has not been described immediately after hematopoietic SCT. A case of humoral rejection was described 9 days after an allogeneic peripheral blood stem cell transplantation. 5 A year earlier, this patient had received a Ktx from her father and stem cells from her HLA-identical sister. The presence of both auto-and alloantibodies and thrombotic microangiopathy was consistent with a humoral rejection. The authors felt the presence of both IgM and IgG allo-antibodies prior to neutrophil recovery suggests that the rejection was a graftversus-graft phenomenon.
Although the rejection episode was eventually controlled with antithymocyte globulin, morbidity and hospitalization were significantly increased. Given the potential consequences, we recommend that MMF should be continued during auto-SCT. The combination of calcineurin inhibitor and MMF has been used without negative impact on engraftment after hematopoietic SCT. 6, 7 Renal function should be monitored closely around the time of engraftment and there should be a low threshold to biopsy the renal allograft. Thrombocytopenia may pose a problem, but pre-biopsy platelet transfusion was effective at preventing bleeding complications. Alloantibody levels may be helpful to determine the immunologic status of the patient. Any rash should be evaluated for autologous GVHD. Rejections should be treated aggressively, as they may be resistant to steroids as illustrated by our case. 
